Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) CEO Sells 6,000 Shares of Stock
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $61.55, for a total value of $369,300.00. Following the completion of the transaction, the chief executive officer now owns 6,000 shares in the company, valued at $369,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded down $0.93 during midday trading on Tuesday, reaching $61.33. The company’s stock had a trading volume of 301,294 shares, compared to its average volume of 512,803. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.63) earnings per share. equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current year.
A number of research analysts recently commented on AGIO shares. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price on the stock. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks reissued a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $75.70.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.